...
首页> 外文期刊>Cardiology Research >Cardiac Resynchronization Therapy Leads to Improvements in Handgrip Strength
【24h】

Cardiac Resynchronization Therapy Leads to Improvements in Handgrip Strength

机译:心脏再同步疗法可提高握力

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: A reduction in skeletal muscle performance measured by handgrip strength is common in heart failure. No trial has investigated the role of cardiac resynchronization therapy, which leads to improvements in cardiac performance, on the function of skeletal muscle in patients with heart failure.Methods: Nineteen patients were recruited, 18 male, age 69 ± 8 years, New York Heart Association class II-IV, QRS duration 173 ± 21 ms and left ventricular ejection fraction 26±8%. Handgrip strength was measured at baseline before, and 6 and 12 months, following cardiac resynchronization therapy. Response was assessed using quality of life questionnaire, 6-minute walk distance, left ventricular end-diastolic volume, and cardiopulmonary exercise testing at the same time points.Results: Fourteen patients were identified as responders, demonstrating significant improvements in all four markers of response. There was no significant difference at baseline in left or right handgrip strength between responders and non-responders. Compared to baseline, handgrip strength significantly increased in responders during follow-up, left (34.4 ± 11.4 to 40.3 ± 11.3 kgf, P < 0.001) and right (35.7 ± 12.5 to 42.2 ± 11.5 kgf, P < 0.001) at 12 months. No such improvement was seen in non-responders.Conclusions: This study demonstrates that positive response to cardiac resynchronization therapy is associated with significant gains in handgrip strength, suggesting that cardiac resynchronization therapy may indirectly lead to secondary gains in skeletal muscle function.Cardiol Res. 2016;7(3):95-103doi: http://dx.doi.org/10.14740/cr475w
机译:背景:在心力衰竭中,通过握力测量的骨骼肌性能下降是常见的。方法:招募了19例患者,其中18例男性,年龄69±8岁,New York Heart,尚无研究调查心脏再同步治疗在改善心脏性能方面对心脏衰竭患者骨骼肌功能的作用。协会II-IV级,QRS持续时间173±21 ms,左心室射血分数26±8%。在心脏再同步治疗之前,之后6和12个月的基线测量握力。使用生活质量问卷,6分钟步行距离,左心室舒张末期容积和同时进行心肺运动测试来评估反应。结果:14例患者被确认为反应者,表明所有四个反应指标均有显着改善。响应者和非响应者之间的基线左右手握力没有显着差异。与基线相比,随访期间反应者的握力明显增强,在12个月时分别为左(34.4±11.4至40.3±11.3 kgf,P <0.001)和右(35.7±12.5至42.2±11.5 kgf,P <0.001)。结论:这项研究表明,对心脏再同步治疗的积极反应与握力的显着提高有关,这表明心脏再同步治疗可能间接导致骨骼肌功能的继发性增高。 2016; 7(3):95-103doi:http://dx.doi.org/10.14740/cr475w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号